KPC Pharmaceuticals Inc banner

KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 9.49 CNY -3.75% Market Closed
Market Cap: ¥7.2B

EV/FCFF

33
Current
82%
More Expensive
vs 3-y average of 18.1

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
33
=
Enterprise Value
¥7.8B
/
Free Cash Flow to Firm
¥198.7m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
33
=
Enterprise Value
¥7.8B
/
Free Cash Flow to Firm
¥198.7m

Valuation Scenarios

KPC Pharmaceuticals Inc is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (18.1), the stock would be worth ¥5.21 (45% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-46%
Maximum Upside
No Upside Scenarios
Average Downside
28%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 33 ¥9.49
0%
3-Year Average 18.1 ¥5.21
-45%
5-Year Average 17.7 ¥5.08
-46%
Industry Average 30.7 ¥8.83
-7%
Country Average 28.8 ¥8.29
-13%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
KPC Pharmaceuticals Inc
SSE:600422
7.2B CNY 33 20.5
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 140.4 39
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 34.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 19 19.5
US
Merck & Co Inc
NYSE:MRK
272.3B USD 24.8 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 42.2 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 21.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 11.6 16.4
P/E Multiple
Earnings Growth PEG
CN
KPC Pharmaceuticals Inc
SSE:600422
Average P/E: 21.4
20.5
10%
2.1
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

In line with most companies in China
Percentile
55th
Based on 4 731 companies
55th percentile
33
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

KPC Pharmaceuticals Inc
Glance View

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
10.17 CNY
Undervaluation 7%
Intrinsic Value
Price ¥9.49
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett